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as stent thrombosis. These events are hypothesized to be associated in part with durable
polymers of current DES. The MiStent SES uses a unique combination of components, a
crystalline formulation of sirolimus and a fully absorbable polymer on a thin-strut, cobalt
chromium stent platform. The polymer coating is eliminated from the stent in 45-60 days
with complete absorption in 90 days. Sirolimus is simultaneously released into the
surrounding tissue as a controlled elution.
Methods: The DESSOLVE II clinical trial is a 2:1 randomized study conducted at 26
sites evaluating the MiStent SES for superiority in late lumen loss as compared to the
control stent, the Medtronic Endeavor Sprint (Santa Rosa, CA). Patients with discrete de
novo lesions (2.5-3.5 mm vessel diameter and27 mm length) in native coronary arteries
were acceptable for inclusion in the trial. A total of 183 patients were randomized into
either the MiStent SES or Endeavor Sprint and patients had follow-up at 30-days, 6, 9, and
12-months post-procedure. Angiography was conducted at 9-months with two subgroups:
38 patients imaged using optical coherence tomography (OCT) and 29 patients partici-
pated in endothelial function testing (EFT).
Results: The MiStent SES was superior to Endeavor for the primary endpoint analysis of
late lumen loss. The OCT revealed a mean of 2% uncovered struts with good suppression
on neointimal hyperplasia. EFT demonstrated an overall return of endothelial function
with no incidence of vasoconstriction in either the test or control group. Additional
secondary endpoint data will be presented.
Conclusions: The MiStent SES is an innovative drug eluting stent with sirolimus in a
fully absorbable polymer demonstrating a superior performance as compared to the
Endeavor Sprint DES. OCT shows stent coverage at 9-months with a return of endothelial
function.
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Background: The aim of this first in human study is to assess safety and performance of
the Passeo-18 Lux Paclitaxel releasing PTA balloon (DCB) versus the uncoated
Passeo-18 balloon catheter (POBA) for the treatment of stenosis and occlusion of
femoropopliteal arteries.
Methods: Between October 2010 and August 2011, 60 subjects presenting with stenosis
or occlusion of femoropopliteal arteries were consecutively enrolled in this international,
multicenter, randomized controlled trial under a 1:1 allocation. Primary endpoint of the
study is late lumen loss (LLL) at 6 months assessed by an independent corelab using
quantitative vascular angiography (QCA). Secondary endpoints are binary restenosis (BR)
at 6 months, target lesion revascularization, change in mean ankle brachial index and
Rutherford classification and major adverse events (MAEs) at 6 and 12 months.
Results: Thirty-four men (56.7%) were enrolled in 5 sites. Mean age was 70.710.1
(range 45-90) years. Half of the subjects were treated with the Paclitaxel releasing balloon
(study group) and the other half with the uncoated balloon catheter (control group). The
majority of subjects presented with hypertension (73.3%), followed by smoking (68.3%),
history of PAD (63.3%), hyperlipidemia (61.7%) and diabetes mellitus (33,3%). Almost
two thirds (56.7%) of the subjects were in Rutherford Class 3 and 26.7% were in Class
2. LLL at 6 months was significantly better with 0.50.7mm in the DCB group versus
1.01.0mm in the POBA group (p0.033). Three (11.5%) subjects presented with BR in
the DCB group versus 9 (34.6%) in the POBA group (p0.048). The overall MAE rate
is identical in both groups with 4 (15%) MAEs each. ABI improvement was the same in
both groups from baseline (0.70.2) to 6 months (0.90.2). Clinical outcome in
Rutherford Class was sligthly better in the DCB group with an improvement from
3.00.8 at baseline to 1.61.4 at 6 months versus 2.90.8 to 1.71.3 in the POBA
group.
Conclusions: Six month Results are consistent with previously published data and
confirm the safety and efficacy of DCB for the treatment of symptomatic femoropopliteal
disease. LLL and BR Results were significantly better in the DCB group compared with
POBA.
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Background: Previous studies of drug-eluting stent (DES) restenosis have shown that
the morphologic pattern of in-stent restenosis (ISR) was an important predictor of
outcomes after plain balloon angioplasty or repeat DES placement. However, there is no
data available on the relationship between the restenosis pattern and angiographical
outcomes after paclitaxel-eluting balloon (PEB) angioplasty.
Methods: From September 2008 to August 2011, 304 lesions were treated with PEB for
ISR lesions after DES implatation. All of the initial DES were implanted in de novo
lesions (Sirolimus-eluting stent: 156, Paclitaxel-eluting stent: 53, Zotarolimus-eluting
stent: 52, Everolimus-eluting stent: 31, Biolimus-eluting stent: 12). We divided these
lesions into two groups: focal lesions and nonfocal lesions, which were diffuse,
proliferative and total lesions. We investigated the angiographic restenosis pattern and the
restenosis rate at follow-up coronary angiography (CAG). Follow-up CAG was per-
formed at 6 months after procedure.
Results: The angiographical follow-up rate was 91.1% (277 lesions: 99 focal lesions, 178
nonfocal lesions). The binary restenosis rate was 18.2% in focal lesions and 29.2% in
nonfocal lesions (p0.04). The figure shows the restenosis patterns at baseline and
follow-up of the lesions which restenosed for the second time. The recurrent restenosis
pattern at follow-up remained the same in 64.3%, became worse in 7.1% and improved
in 28.6%.
Conclusions: After PEB angioplasty for DES ISR lesions, the morphologic pattern of
ISR is also an important predictor of the outcomes. Most of the recurrent ISR patterns are
the same or better than preprocedural ISR patterns.
Pattern at
baseline Types of change
Pattern at
follow-up
Focal 18 lesions Improved 0 30 lesions
Same 15 lesions
Worse 3 lesions
Diffuse 37 lesions Improved 14 lesions 27 lesions
Same 21 lesions
Worse 2 lesions
Proliferative 7 lesions Improved 1 lesions 7 lesions
Same 6 lesions
Worse 0
Total 8 lesions Improved 6 lesions 6 lesions
Same 2 lesions
Worse 0
TCT-587
Drug-Coated Balloon For De Novo Coronary Lesions: Results From The
Valentines II Trial
Ron Waksman1, Antonio Serra2, Alfredo Rodriguez3,
Rembert Pogge von Strandmann4, Stefanie Stahnke4, Rebecca Torguson5,
Joshua Loh6, Fazila Malik7
1Georgtown University, Washington, DC, 2Hospital de Sant Pau y Santa Creu,
Barcelona, Spain, 3Otamendi Hospital, Buenos Aires, Argentina, 4Eurocor GmbH,
Bonn, Germany, 5Washington Hospital center, washington, DC, 6Medstar
Washington Hospital Center, Washington, DC, 7National Heart Foundation
Hospital & Research Institute, Dhaka, Bangladesh
Background: Drug-coated balloons (DCB) have emerged as a potential alternative in
treating in-stent restenosis; however, their role in the treatment of de novo lesions is
unclear. This study aimed to evaluate the safety and efficacy of the second-generation
DIOR DCB as an adjunct to plain old balloon angioplasty (POBA) for the treatment of de
novo coronary lesions.
Methods: Valentines II was designed as a prospective, multicenter, multinational,
Web-based registry. Eligible patients with stable or unstable angina, and/or documented
ischemia on stress testing with de novo lesions of 50% stenosis were prospectively
enrolled. Patients underwent POBA followed by DCB. In cases of suboptimal angio-
graphic success (TIMI flow 3 and/or residual stenosis of 30%), additional bail-out
bare metal stenting (BMS) was left to the operator’s discretion. The primary endpoint was
6-9 months major adverse cardiac events (MACE: all cause death, myocardial infarction,
target vessel revascularization and vessel thrombosis). A subset of patients underwent
angiography follow-up.
Results: 109 lesions in 103 patients were treated. Mean age was 62.6  10.2 years;
79.6% were male. Lesion stenosis at baseline and post treatment was 83.3  9.5% and
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10.4 10.6%, respectively. Procedural success was 99%. Coronary dissections occurred
in 14.7%, and bailout BMS was required in 13 patients (11.9%). Mean follow-up was 7.5
months; follow-up rate was 99%. Cumulative MACE at follow-up was 8.7%, with 1%
all-cause death, 1% myocardial infarction, 6.9% overall target vessel revascularization; of
which 2.9% were target lesion revascularizations, and no vessel thrombosis. Angiographic
follow-up of a subset of patients (n26) demonstrated late luminal loss of 0.30  0.36
mm and 0.33  0.37 mm for the in-DCB and in-segment analyses, respectively.
Conclusions: The Valentines II trial demonstrated the safety and efficacy of second-
generation DIOR DCB as adjunct to POBA in an all-comer population with de novo
coronary lesions. This approach achieved high procedural success with acceptable rates of
bailout stenting and low MACE rates at mid-term follow-up, and offers an attractive
alternative for revascularization of patients who are not good candidates.
TCT-588
Cost-effectiveness of paclitaxel-coated balloon angioplasty for treatment of
coronary restenosis in bare-metal stents
Klaus Bonaventura1, Alexander Leber2, Christian Sohns3, Mattias Roser4,
Leif-Hendrik Boldt4, Wilhelm Haverkamp4, Marc Dorenkamp4
1Klinikum Ernst von Bergmann, Potsdam, Germany, 2Sunnybrook Health Science
Centre, Toronto, Ontario, 3Heart Center, Georg-August-University of Göttingen,
Göttingen, Germany, 4Charité – Universitätsmedizin Berlin, Campus Virchow-
Klinikum, Berlin, Germany
Background: In-stent restenosis (ISR) is a persistent problem limiting the long-term
success of percutaneous coronary intervention. Recent studies have demonstrated safety
and efficacy of drug-eluting balloon (DEB) angioplasty for the treatment of coronary ISR.
The cost-effectiveness of this practice is unknown.
Methods: A Markov state-transition decision analytic model was used to assess the
comparative cost-effectiveness of two common treatment strategies for bare-metal stent
(BMS)-ISR: stenting with paclitaxel-eluting DES (drug-eluting stent) versus paclitaxel-
eluting balloon angioplasty (SeQuent Please). The model accounted for varying proce-
dural efficacy rates, complication rates, and cost estimates. Data on procedural outcomes
associated with both treatment strategies were derived from the literature, and the cost
analysis was conducted from a German health care payer perspective. Effectiveness was
expressed as life-years gained. Cost-effectiveness was calculated by dividing the differ-
ence in mean costs by the difference in effectiveness.
Results: In the base-case analysis, initial procedure costs amounted to $4,497.27 for DEB
angioplasty and to $4,128.81 for DES implantation. Over a 12-month time horizon, the
DEB strategy was found to be less costly ($5,154.47 versus $6,619.98) and slightly more
effective in terms of life expectancy (0.983 versus 0.976 years) than the DES strategy.
Extensive sensitivity analyses indicated that, in comparison with DES implantation, the
cost advantage of the DEB strategy was robust to clinically plausible variations in the
values of key model input parameters. The variables with the greatest impact on base case
Results were the duration of dual antiplatelet therapy after DEB angioplasty, the use of
generic clopidogrel, and variations in the costs associated with the DEB device.
Conclusions: DEB angioplasty is a cost-effective treatment option for coronary BMS-
ISR. The higher initial costs of DEB are more than offset by later cost savings,
predominantly as a result of reduced medication costs. DEB angioplasty can be regarded
as one of the rare innovative medical interventions that are cost-saving at equal or even
increased effectiveness.
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Background: In spite of all the technical developments that have taken place in coronary
artery disease treatment, small diffusely calcified vessels are yet challenging. Rotational
atherectomy (ROTA) has an undisputed role in the debulking of severely calcified
arteries, followed by drug eluting stent implantation for best long term Results. There are
cases, however, where delivering a stent proves to be impossible or inappropriate. In such
patients (pts) drug eluting balloons (DEB) could provide a therapeutic option. AIMS: We
present the preliminary Results of the experience of 3 cardiovascular intervention centers
on the use of ROTA followed by DEB (ROTA-DEB).
Methods: All data on pts submitted to rotablation is prospectively collected in a database.
Pts in which ROTA-DEB was performed, accepted to angiographic follow-up (Fup-
angio) after a minimum of 6 months. Lesions were assessed by QCA at the time of
intervention. Post ROTA-DEB and at Fup, QCA was done after intra coronary
administration of nitrates in the same plane as basal QCA and along the length of the
DEB.
Results: In our multicenter registry, from 1/6/2009 to 31/5/2012, 204 consecutive pts
were submitted to ROTA, of which 21 (10.3%) were followed by DEB (32 balloons
(average size: 2.45 (2-4) mm x 21.66 (15-30) mm). Most common indications for DEB
were: distal vessel  2 mm (59.4%) and difficulties in stent delivering (25%). Angio-
graphic success was achieved in all but 2 lesions(91%): 1 final QCA  50% and 1
required bail-out stenting. All pts showed a marked improvement in clinical status. At 12
months, freedom from major cardiac adverse events was 90%. Fup-angio(refused by 3
pts)was obtained at a median of 424  254 days. QCA analysis showed an average late
luminal loss (LLL) of -6% (-62% to 	75%). LLL  50% was present in 1 pt.
Conclusions: Although these are still small numbers, Results seem very promising,
considering the complexity of the lesions. For very severe, diffusely calcified coronary
artery disease, ROTA-DEB constitutes a good therapeutic option when a stent cannot be
implanted.
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Background: The efficacy of paclitaxel-eluting balloon (PEB) for in-stent restenotic
lesions is proven; however, its efficacy for recurrences after drug-eluting stent (DES)
implantation for in-stent restenosis (stent in stent lesions) remains unclear. The aim of this
study was to investigate the efficacy of PEB in patients with recurrences after DES
implantation for in-stent restenosis.
Methods: From November 2004 to December 2011, 159 consecutive lesions who
underwent revascularization for recurrences after DESs for in-stent restenosis were
enrolled in this study [77 treated with PEB and 82 treated with conventional balloon
angioplasty (BA)]. Follow-up angiogram was obtained 6 months after the procedure. We
compared characteristics of patients and lesions between the two groups (PEB group vs
BA group).
Results: No significant differences were observed in clinical characteristics between the
two groups. Angiographic characteristics before the procedure were similar between the
two groups (Reference diameter: 3.07  0.56 mm vs 3.07  0.55 mm, p  0.9; Lesion
length: 18.0  15.0 mm vs 15.0  11.7 mm, p  0.1; Minimal lumen diameter: 0.85 
0.53 mm vs 0.95  0.58 mm, p  0.3). Acute gain was also similar between the two
groups (1.33  0.69 mm vs 1.26  0.68mm, p  0.5). At the 6-month angiographic
follow-up (follow-up rate: 94%), the incidence of recurrent restenosis (29.2% vs 59.7%,
p  0.0003) and target lesion revascularization (23.6% vs 40.3%, p  0.036) was
significantly lower in the PEB group than in the BA group. Late lumen loss was
significantly lower in the PEB group than in the BA group (0.46  0.63 mm vs 0.82 
0.73 mm, p  0.0017).
Conclusions: In patients with recurrent restenosis after DES implantation for in-stent
restenosis(stent in stent lesions), PEB provided much better clinical, angiographic
outcomes than conventional BA.
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Background: In comparison to the original PACCOCATH formulation, second gener-
ation PCB have improved coating uniformity and decreased drug content variability by
modifying coating Methods and processes. In this study, we intended to evaluate the
differences in biological efficacy and vascular healing response of 2nd generation PCB in
comparison to a 1st generation balloons technologies containing identical coating
formulation and drug concentration.
Methods: A total of 18 Ilio-femoral arterial segments of 8 FHS were included in the
study. At baseline overstretch balloon injury followed by self-expanding BMS implan-
tation was performed. Two weeks following initial injury, all stents were randomized to
either a 2nd gen. PCB (n6, Cotavance V2, Medrad), 1st gen. PCB (n6, PACCO-
CATH, Medrad) or POBA (n6, control group). Imaging evaluation (QVA, IVUS) was
conducted in all animals at baseline, treatment time (2 weeks) and 28 days following
treatment. At termination, stented segments were harvested for histopathological evalu-
ation.
Results: At last follow up angiographic %DS was significantly reduced in both
generations of PCBs when compared to controls (2nd Gen PCB: 11.511.1% vs. 1st Gen
PCB: 21.911.0% vs. POBA: 46.510.9%; p0.01). These findings were confirmed by
histopathological analysis (see table) displaying an 35% reduction of %AS and
neointimal thickness in both PCB groups. Vessel healing defined as fibrin deposition,
neointimal maturity and medial cell loss scores was significantly improved in 2nd Gen PCB
when compared to 1st Gen PCB. Endothelialization was completed in all three groups.
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